Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) – Equities researchers at Roth Capital boosted their Q2 2025 earnings estimates for shares of Fortress Biotech in a research report issued on Tuesda… [+3929 chars]...
Read moreWolverine Trading LLC purchased a new position in shares of Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Secu… [+3624 chars]...
Read moreMIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (Fortress), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value … [+6915 chars]...
Read moreNational TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2… [+11116 chars]...
Read more